ABSTRACT OBJECTIVES This study aimed to evaluate the impact, safety, and success of atrial fibrillation (AF) ablation in adults with congenital heart disease (ACHD) transferring ablation strategies established in normal hearts.
RESULTS
Of the 57 patients, 30 underwent corrective surgery, 6 underwent palliative surgery, 5 had catheter interventions, and 16 were natural survivors. Follow-up was available for all patients (median 41 AE 36 months). The median duration of cyanosis was 9.2 AE 19.7 years, and the time of volume or pressure overload prior to corrective surgery or intervention was 26.1 AE 21.2 years and 18.1 AE 15.8 years, respectively. The Kaplan-Meier estimate for arrhythmia-free survival following the index ablation procedure was 63% for 1 year and 22% for 5 years. Performing subsequent ablation procedures (2.0 AE 0.5), the Kaplan-Meier estimate significantly improved, with 99% for 1 year and 83% for 5 years (p < 0.01). Five patients died during follow-up due to their underlying CHD condition or underwent transplantation.
CONCLUSIONS AF ablation strategies established in normal hearts can be transferred to ACHD. The treatment is safe and effective with acceptable long-term results. Varying anatomical pre-conditions and the heterogeneous population itself are challenging and contribute toward a higher reablation rate. Therefore, AF ablation in ACHD should be reserved for dedicated and highly specialized teams. (J Am Coll Cardiol EP 2018; -:--- The congenital cardiac anomalies were classified according the 32nd Bethesda consensus document (4) into their levels of complexity: mild (61.4%), moderate (17.5%), and severe (21.1%) ( Table 1) AF Therapy in Adults With Congenital Heart Disease -2 0 1 8 : ---
